

Noninvasive Diagnostics Centre **VIVERRA®**



Unhappy prognosis: Cancer will triple increase in future

Number of people with cancer will triple By 2030, occurrence of cancer around the world will treble. Medicine can already cure number of diseases, but the risk of oncological diseases is still rapidly growing.

Unhappy prognosis: Cancer will triple increase in future

It is a fact that occurrence of cancer doubled in last three decades of last century. It is expected that between 2000 and 2020 the cancer occurrence will double again and at 2030 will triple the numbers. Around 2030 there will be 26,4 mil. people diagnosed with cancer and 17 mil. people per year will die by this disease around the world.

American Institute for cancer research, Washington DC

WHO — we have to do something!

6,2 mil. people died in 2000 by cancer.
10 mil. people developed cancer in the
same year. There will be 16 mil. people
diagnosed with cancer and 10 mil. people
per year will die around the year 2020 if
we will not change our approach to cancer
prevention and treatment.

WHO (World Health Organization)

Breast cancer — a mass killer

There is a woman diagnosed with breast cancer every 2.5 minutes In the European Union (EU).




Every 7.5 minutes a woman die from the effects of breast cancer..

Stella Kyriakides

President of Europa Donna, European Breast Cancer Coalition, 2004

Breast cancer in EU and SVK

Age-standardized occurrence and mortality rate, breast cancer in women in the EU countries, the estimates in 2006



Slovakia



- about 2,000 cases of women and about 30 cases of men every year
- **upward trend for disease occurrence**
- **high incidence of late stages**



Global trend



Is it possible to change emphasis from treatment to prevention?

Today, only 3% from all medical expenses is used on prevention in OECD countries.

As the World Health Organization (WHO) claims, it is possible to avoid **80% of heart attacks, strokes, diabetes and 40 % of cancers** with prevention.

VIVERRA® Scheme — prevention in practice


VIVERRA® Scheme is building a network of special medical units (diagnostic centers) using latest modern technology to completely diagnose and analyze human body.

Noninvasive Diagnostic Centre is a key element of Scheme.


There is more workable options in Scheme — clinics, healing centers and more....

The Mission and purpose of VIVERRA® Scheme is to offer our clients PAINLESS, ACCURATE and FAST Service.

Tumor Growth — and when can we find it?



What do we look at



Noninvasive hematology analyzer examination



Neinvazívny hematologický analyzátor

Priezvisko, Meno: xxx 15.5.2012

Pohlavie:1 Vek:58 Váha:102 Pulz:1

No Exponent

Krvný obraz

1	Hemoglobín g/l
2	Erytrocyty v 1mm ³ . E10 ¹² /l
3	Lymfocyty. %
4	Leukocyty E10 ⁹ /l
5	N.seg. %
6	PW. mm/h
7	Eozinofily. %
8	Monocyty. %
9	Neutrofy palčičky %

Výmena elektrolytov

10	Koncentrácia Ca. mmol/l
11	Koncentrácia Mg. mmol/l
12	Koncentrácia K. mmol/l
13	Koncentrácia Na. mmol/l

Koagulačný systém:

14	Začiatok koagulácie krv. min
15	Koniec koagulácie krv. min
16	Trombocyty. tis.
17	Hematokrit. %

Enzymatický systém:

18	AST. mmol/l
19	ALT. mmol/l
20	AST. E/l
21	ALT. E/l
22	ALT/AST
23	Amyláza g/hod
24	Bilirubín celkový. mkmol/l
25	Bilirubín konjugovaný. mkmol/l
26	Bilirubín nekonjugovaný.
27	Celkom bielkovín. g/l

Prenos a spotreba kyslíku:

28	Hustota plazmy.
29	Objem cirkulujúcej krvi. ml/kg
30	Minútový prietok cirkulujúcej krvi l/min
31	Rýchlosť oxygenácie ml/sek
32	Plocha výmeny plynov. m ² .
33	Vitálna kapacita pľúc. cm ³

No Exponent

37	Kardiálna ejekcia. ml
38	Spotreba O ₂ na 1kg. ml/min/kg
39	Pľúcna ventilácia. l/min
40	Spotreba O ₂ . ml/min
41	Myokardová spotreba O ₂ . ml/min
42	Deficit cirkulujúcej krvi. ml
43	Vitálna kapacita pľúc v stave expirácie. cm ³ .
44	Max. prietok vzduchu. l/min
45	Test Tiffeneau. %

46	Fibrinogén. g/l
47	Koncentrácia kreatinínu. mkmol/l
48	Dopamin-B-hydroláza. nmol/ml/min
49	Koncentrácia kyseliny mliečnej. mmol/l
50	Koncentrácia močoviny. mmol/l
51	Koncentrácia glukózy. mmol/l
52	Triglyceridy. mmol/l

53	Cholesterol. mmol/l
54	B-lipoprotein. mmol/l
55	B-lipoprotein. g/l.
56	LDLipoproteín. mmol/l
57	LDL veľmi nízkej hustoty. mmol/l
58	HDLipoproteín. mmol/l

Prenos a spotreba CO₂:

59	Vylučovanie CO ₂ . ml/min
60	Obsah CO ₂ v arteriálnej krvi. %
61	Obsah CO ₂ vo venóznej krvi. %
62	Rýchlosť tvorby CO ₂ . ml/min

Pomer krvného obehu vnútorných orgánov a celkového

63	Prietok krvi myokardom. %
64	Prietok krvi kostrovým svalstvom. %
65	Cerebrálny prietok krvi. %
66	Hepatický a portálny prietok krvi. %
67	Renálny prietok krvi. %
68	Prietok krvi kožou. %
69	Prietok krvi ostatnými orgánmi. %

Krvný obeh vnútorných orgánov ml/min:

70	Prietok krvi myokardom. ml/min
71	Prietok krvi kostrovým svalstvom. ml/min
72	Cerebrálny prietok krvi. ml/min
73	Hepatický a portálny prietok krvi. ml/min
74	Renálny prietok krvi. ml/min
75	Prietok krvi kožou. ml/min

No Exponent




80	QT interval v sek	0.355-0.4	0.402
81	QRS interval v sek	0.065-0.1	0.079
82	Kontrakcia myokardu ľavej srdcovej komory. %	60-85	41.423
83	Systolický arteriálny tlak	0-0	113.256
84	Diastolický arteriálny tlak	0-0	75.608
85	Odpor v malom krvnom obehu. din/cm2sek	140-150	136.506
86	Šírka tretej ventrikulárnej komory mozgu. mm	4-6	13.116
87	Tlak likvoru. mm.H ₂ O	90-145	367.272
88	Centrálny venózy tlak. mm.vod.st.	70-150	19.284
89	Čas cirkulácie krvi vo veľkom krvnom obehu. sek	16-23	22.834
90	Čas cirkulácie krvi v malom krvnom obehu. sek	4-5.5	9.754

91	Spektrálna vlnová dĺžka absorpcie CO ₂ v krvi. mkm	4.165-4.335	4.958
92	Spektrálna vlnová dĺžka absorpcie N ₂ O v krvi. mkm	3.7828-3.9372	2.415
93	Koncentrácia H ₂ v žalúdočnej štave.	1.2-1.7	1.978
94	pH	7.36-7.45	7.408
95	SH.	7.32-7.4	3.033
96	Činnosť srdca. Joule	0.692-0.788	1.409
97	Kyselina glutamová. mmol/l	0.0045-0.0055	0.005
98	Kyselina tyrozínová. mg/%	1.4-1.8	1.765
99	Svalová kreatín kináza. mkmol/min/kg	473-483	466.659
100	Srdcová kreatín kináza. mkmol/min/kg	35.1-38.1	37.997
101	Glykogén. mg/%	11.7-20.6	17.048
102	Výdierpanie energetických zdrojov. kkal/kg/min	1.23-4.3	30.973
103	Pracovné hladiny spotreby O ₂ . %	45-60	74.622
104	Čas jednotkového zaťaženia. min	3-10	1.588
105	Respiračný koeficient.	0.8-1.2	1.246
106	Tyrozín. mkmol/l.	0.044-0.072	0.066
107	Cerebrálny prietok krvi v prepočte na 100g tkaniva. ml/100g	50-55	46.311
108	Urínový testosterón. mkmol/24 hod	6.93-17.34	3.678
109	Urínové estrogény celkom. nmol/24 hod	17.95-64.62	109.442
110	Extra celulárna tekutina. %	21-23	24.101
111	Celulárna tekutina. %	39-42	41.978
112	Celková tekutina. %	53-60	48.037
113	Prietok krvi 1 g. tkaniva štítnej žľazy. ml	3.7-4.3	3.795
114	Prietok krvi 1 g. cerebrálneho tkaniva. ml	2.9-3.2	4.167
115	Index tkaninovej extrakcie O ₂ . ml	0.26-0.34	0.343
116	Bazálny tonus Oddého zvieráča. mm Hg	39-41	40.051
117	Index protrombhu. %	75-104	72.581


Predbežná počítačová analýza pre ošetrovateľov lekárov:
Hydrocephalus. Need advice neurologist, endocrinologist.

1430-1490	1377.989
500-535	372.180

Myocard examination by ECG cardiovisor



Central hemodynamics examination



Breast examination by microwave radiometry

Examination Protocol

Season: Солнечн

Organ: breast

Hospital:

Name: Birth Date:

Patient Number: 15253

General Practitioner: Day:

C.: Diam.: 20

Cycle: menopausa

Medical History: Cancer family history:

Physical: BL


Mammography: BL (right)

Ultrasound:


Biopsy:

Histology:




Internal Temperature Field






Skin Temperature Field





Measurement Station


Electroimpedance mammography examination




Dynamic thermography examination



Rakovina prs







Mastopathy



Melanoma

Dynamic thermography examination



What can we treat primary in the center of preventive diagnostics

Trophic ulcers (venous ulcers)

Periodontitis (pyorrhea)

Scleroderma

Pressure ulcers (bed sores)

Suppurative - necrotic lesions (diabetes)

Psoriatic and rheumatic arthritis


Gynecology – endocervicitis, cervical cancer

An acute and chronic inflammations of the middle ear and nasal cavities

Do we see solution out ...

**Food –
the need of
the organism**

The body daily consumption
95+ nutritional components



Traces and toxic elements analysis of human body



Recommendation of preventive individual supplementation

Preventívny program				
Suplement		ráno	poludnie	večer
Acerola 30 mg denne, po šesť mesiacov		1	1	0
Omega 3 (EPA 180 mg, DHA 120 mg) denne, po šesť mesiacov		pred jedlom	pred jedlom	0
Multivitamín denne, po šesť mesiacov		0	30 minút pred jedlom	0
Sylimarol 70 mg denne, po šesť mesiacov		0	po jedle	0
Vápník 300 mg + Horčík 125 mg denne, po šesť mesiacov		1	0	1
		po jedle	0	po jedle
Sylimarol 70 mg denne, po tri mesiace	0	po jedle	1	1
Vápník 300 mg + Horčík 125 mg denne, po tri mesiace	0	po jedle	po jedle	0
Glukozamín 500 mg denne, po tri mesiace	0	po jedle	0	0

Výživový program

Suplement				
Acerola 30 mg denne, po tri mesiace				
Omega 3 (EPA 180 mg, DHA 120 mg) denne, po tri mesiace				
B-complex denne, po tri mesiace				
Ananas - tráviace enzýmy denne, po dva mesiace				
Prírodná vláknina denne, po dva mesiace				
Sylimarol 70 mg denne, po tri mesiace				
Vápník 300 mg + Horčík 125 mg denne, po tri mesiace				
Glukozamín 500 mg denne, po tri mesiace				

Technical and economic parameters of Scheme for the client

Noninvasive examination

We examine without X-ray in any form

The results are available to us right after examination

We evaluate results right after examination

We do not waste our client's time

We offer financially acceptable parameters

We save our clients the costs of subsequent treatment, or eliminate the need for therapy by effective prevention

We are able to capture preclinical stages of cancer diseases

Technical and economic parameters of Scheme for investor

Low investment costs of technologies regarding the efficiency when compared with classical technologies

Low operating costs

Automatic upgrades to new versions of technologies (hardware and software)

By entering the Scheme, every partner will get access to our research findings from data collected and analyzed by our Automated Data Processing Program

Market guarantee – Scheme will guarantee your regional exclusivity in overall concept of coverage agreement

Additional income guarantee – Scheme will guarantee your additional income from your exclusive food supplements sales agreement

Marketing background

Scheme is based on Pay Cash principals (Pay Cash Clients). Considering situation on the Health Market, VIVERRA® Program is not expecting any payments for treatments from Health Insurance Companies.



Targeted groups:

- A.** Financially secure clients - about 10% of population - accept 3%.
- B.** Long Term suffering clients - about 8% of population - accept 2%.
- C.** Genetically predisposition clients with cancer predisposition - about 33% of population - accept 5 %.

Overall calculations expects that the real clientele is **about 10% of EU population.**